Eesti - eesti - Ravimiamet

statens serum institut - tuberkuloosi tekitaja, elus, nõrgestatud - süstesuspensiooni pulber ja lahusti - 0,75mg 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

instituto grifols s.a. - inimese normaalne immunoglobuliin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - suguhormoonid ja immunoglobuliinid, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Euroopa Liit - eesti - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - kartsinoom, squamous cell - antineoplastilised ained - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi b.v. - türeotropiin alfa - kilpnäärme kasvajad - anterior hüpofüüsi lobe hormoonid ja nende analoogid, hüpofüüsi ja hüpotaalamuse hormoonid ja nende analoogid - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - inaktiveeritud split gripiviirus, mis sisaldab antigeeni, mis vastab a / california / 07/2009 (h1n1) -kasutatud tüvele, mida kasutatakse nymc x-179a - influenza, human; immunization; disease outbreaks - gripivaktsiinid - a (h1n1) v 2009 viirusega põhjustatud gripi profülaktika. pandemrix´i võib kasutada ainult siis, kui soovitatavad iga-aastased kolmevalentsed / neljavalentsed maailma terviseorganisatsiooni puuduvad ja kui vajalikuks peetakse immuniseerimist (h1n1) v vastu (vt lõigud 4. 4 ja 4. pandemrix tuleks kasutada vastavalt euroopa liidu arendus.

Euroopa Liit - eesti - EMA (European Medicines Agency)

baxter holding b.v. - doksorubitsiini vesinikkloriid - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - antineoplastilised ained - caelyx pegylated liposomal on näidatud:kui monotherapy patsientidel metastaatilise rinnavähi, kus on suurem südame riski;ravi kaugelearenenud munasarja vähk naistel, kes ei ole suutnud esimese-line platinum põhineva keemiaravi raviskeemi;koos bortezomib ravi järk-järgulise hulgimüeloom patsientidel, kes on saanud vähemalt ühe eelneva ravi ja kes on juba läbinud või on sobimatud luuüdi siirdamine;raviks aids-iga seotud kaposi on sarkoom (ks) patsientidel, kellel on madal cd4 loeb (.

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Euroopa Liit - eesti - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubitsiini vesinikkloriid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastilised ained - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Euroopa Liit - eesti - EMA (European Medicines Agency)

teva b.v. - arseentrioksiid - leukeemia, promüelotsüütne, äge - antineoplastilised ained - trisenox on näidustatud remissiooni induktsioon, ja konsolideerimise täiskasvanud patsientidel, kellel on:Äsja diagnoositud madal-vahe-risk ägeda promyelocytic leukeemia (avp) (valgete vereliblede arv, ≤ 10 x 103/µl) koos kõik‑trans‑retinoolhappe (atra)taastekkinud/tulekindlad äge promyelocytic leukeemia (avp) (varasem ravi peab olema lisatud retinoid ja keemiaravi), mida iseloomustab juuresolekul, t(15;17) translokatsioon ja/või olemasolu pro-myelocytic leukeemia/retinoic-happe-retseptor alfa (pml/rar-α) geeni. vastuse määr muude ägeda müeloidse leukeemia alatüüpi, et arseentrioksiid ei ole uuritud.

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxo group ltd. - amprenaviir - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - agenerase kombinatsioonis teiste retroviirusevastaste ravimitega on näidustatud proteaasi inhibiitori (pi) raviks hiv-1 nakatunud täiskasvanutel ja üle 4-aastastel lastel. agenerase kapsleid tuleb tavaliselt manustada amprenaviiri farmakokineetilise võimendajana koos ritonaviiri väikeste annustega (vt lõigud 4. 2 ja 4. amprenaviiri valik peaks põhinema patsiendi individuaalsel viiruse resistentsustestil ja patsiendi ravi ajaloos (vt lõik 5). kasu agenerase võimendatud koos ritonaviiri ei ole tõendatud, pi nave patsientidel (vt lõik 5.